Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation Polymorphism

5 Mar 2009

Abstract excerpt

Oxycodone is O-demethylated by CYP2D6 to oxymorphone which is a potent micro-receptor agonist. The CYP2D6 oxidation polymorphism divides the Caucasian population in two phenotypes: approximately 8% with no enzyme activity, poor metabolizers (PM) and the remainder with preserved CYP2D6 activity, extensive metabolizers (EM). The objective of the study was to determine if the analgesic effect of oxycodone in human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pain Management and Opioid Use
Share to Pain Mechanisms and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 19281600
DOI: 10.1111/j.1742-7843.2009.00378.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation PolymorphismPMID 19281600Read ↗

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.Semantic proximity Read ↗

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective MetabolismSemantic proximity Read ↗

Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.Semantic proximity Read ↗

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.Semantic proximity Read ↗

Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.Semantic proximity Read ↗

Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?Semantic proximity Read ↗

Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.Semantic proximity Read ↗

Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.Semantic proximity Read ↗

CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)Semantic proximity Read ↗

Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid AnalgesicsSemantic proximity Read ↗

The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.